sever
global
spread
outbreak
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
highlight
risk
human
health
pose
emerg
viral
diseas
emphas
need
specif
therapeut
agent
instead
reli
exist
broadli
activ
antivir
compound
develop
rapid
screen
assay
essenti
antivir
drug
discoveri
thu
screen
system
antisarscov
agent
develop
evalu
compound
potenc
specif
cytotox
initi
screen
phase
cell
line
engin
constitut
express
enhanc
green
fluoresc
protein
egfp
use
detect
antivir
potenc
sarscov
infect
test
antivir
specif
test
use
porcin
coronaviru
transmiss
gastroenter
viru
tgev
cytotox
assay
without
viru
challeng
assay
system
involv
minim
manipul
assay
setup
facilit
autom
readout
minim
risk
associ
hazard
virus
suitabl
assay
system
drug
discoveri
demonstr
screen
small
molecul
compound
result
show
assay
appli
highthroughput
screen
identif
inhibitor
select
activ
sarscov
sar
infecti
diseas
high
mortal
rate
caus
human
coronaviru
sarscov
ksiazek
et
al
sever
global
spread
sar
outbreak
led
search
specif
antivir
compound
sarscov
result
vitro
studi
case
report
clinic
publish
consensu
treatment
yet
establish
major
effort
made
understand
mechan
sarscov
replic
order
identifi
drug
target
specif
antivir
compound
chu
et
al
liu
et
al
thiel
et
al
vastag
wu
et
al
coronavirus
envelop
positivestrand
rna
virus
initi
infect
suscept
cell
bind
human
angiotensin
convert
host
cell
membran
via
viral
protein
li
et
al
xu
et
al
follow
receptor
bind
membran
fusion
infecti
genom
rna
deliv
cytoplasm
viral
gene
express
initi
result
translat
two
replicasetranscriptas
polyprotein
two
enzym
respons
replic
viral
genom
well
gener
multipl
subgenom
mrna
includ
encod
structur
protein
spike
membran
e
envelop
n
nucleocapsid
de
haan
et
al
complex
set
regulatori
mechan
control
viral
gene
express
addit
virusencod
enzym
helicas
proteas
crucial
product
infecti
viru
particl
thiel
et
al
progeni
virion
assembl
endoplasmat
reticulumgolgi
apparatu
releas
infect
cell
exocytosi
viral
entri
assembl
process
well
enzymat
step
involv
viral
replic
constitut
potenti
target
antivir
therapi
understand
mechan
viral
replic
key
step
toward
identif
effect
drug
viru
develop
rapid
screen
assay
also
essenti
antivir
drug
discoveri
present
standard
infect
assay
sarscov
base
viral
infect
cell
follow
visual
monitor
cytopath
effect
cpe
ksiazek
et
al
lowthroughput
natur
assay
format
limit
use
effici
screen
larg
chemic
librari
studi
describ
develop
stabl
cell
line
suscept
sarscov
constitut
express
egfp
use
autom
screen
inhibitor
viru
activ
high
degre
correl
viru
replic
reduc
egfp
signal
expect
highli
cytopath
virus
sarscov
background
egfp
signal
rapidli
reduc
extens
cell
death
specif
select
compound
activ
sarscov
screen
assay
determin
parallel
screen
cytotox
inhibit
porcin
coronaviru
use
similar
assay
format
set
assay
use
screen
test
panel
randomli
chosen
chemic
compound
demonstr
applic
drug
discoveri
porcin
kidney
cell
line
african
monkey
kidney
cell
line
kindli
provid
dr
k
andri
j
jprd
beers
belgium
dr
g
van
ham
institut
tropic
medicin
antwerp
belgium
respect
cell
line
maintain
dulbecco
modifi
eagl
medium
dmem
cambrex
bioscienc
walkersvil
walkersvil
md
supplement
fetal
calf
serum
fc
highclon
logan
ut
lglutamin
invitrogen
carlsbad
ca
gentamycin
invitrogen
packag
cell
line
retropack
purchas
bd
bioscienc
clontech
palo
alto
ca
grown
rpmi
medium
invitrogen
supplement
fc
gentamycin
retrovir
vector
plnce
contain
egfp
code
sequenc
cytomegaloviru
immediateearli
promotor
kind
gift
dr
e
kandel
univers
illinoi
chicago
il
sarscov
strain
obtain
center
diseas
control
prevent
cdc
atlanta
ga
tgev
strain
obtain
j
jprd
beers
belgium
antibodi
direct
purchas
r
system
europ
abingdon
uk
produc
retrovirus
egfp
gene
deliveri
cell
transfect
plnce
use
lipofectamin
invitrogen
accord
manufactur
instruct
supernat
transfect
cell
collect
use
transduc
cell
transduc
cell
incub
day
c
clone
cell
line
screen
homogen
high
egfp
signal
fluoresc
activ
cell
sort
fac
clone
also
analyz
suscept
sarscov
tgev
infect
growth
capac
seed
cellsml
monitor
egfp
signal
day
constitut
egfp
express
cell
line
design
viru
cultur
screen
assay
carri
certifi
biosafeti
laboratori
cell
inocul
tgev
cell
inocul
sarscov
subsequ
incub
humidifi
incub
c
co
day
major
cell
show
cpe
cell
cultur
supernat
clarifi
centrifug
g
min
store
c
use
cell
cultur
infecti
dose
ccid
determin
titrat
cell
depend
viru
use
serial
fivefolddilut
step
day
incub
c
plate
inspect
cpe
test
compound
serial
dilut
fourfold
cell
cultur
medium
mix
ccid
tgev
ccid
sarscov
cell
correspond
final
concentr
cellsml
blackview
plate
corn
corn
ny
plate
seal
ga
permeabl
membran
incub
humidifi
incub
c
co
day
well
examin
egfp
express
use
argon
laserscan
microscop
microscop
set
excit
nm
emiss
nm
fluoresc
imag
well
convert
signal
valu
result
express
ec
valu
defin
concentr
compound
achiev
inhibit
virusreduc
egfp
signal
compar
untreat
virusinfect
control
cell
test
cytotox
cell
incub
serial
compound
dilut
describ
absenc
viru
challeng
cytotox
concentr
cc
determin
compar
egfp
signal
treat
well
control
well
contain
untreat
cell
calcul
similarli
ec
two
select
indic
si
calcul
cytotoxicityantivir
activ
si
provid
measur
rang
compound
effect
without
cytotox
calcul
ratio
cc
ec
tgevsarscov
si
repres
specif
compound
inhibit
sarscov
tgev
calcul
ratio
tgev
ec
sarscov
ec
valid
reduc
egfp
express
marker
viru
activ
determin
titrat
sarscov
stock
cell
calcul
titer
base
egfp
signal
cpe
similar
experi
perform
use
tgev
cell
determin
sensit
assay
defin
lowest
viru
titer
result
detect
decreas
egfp
signal
serial
dilut
sarscov
tgev
stock
ad
respect
indic
cell
egfp
signal
record
describ
screen
assay
determin
intraand
interexperi
reproduc
cellsml
ad
togeth
ccid
sarscov
well
plate
addit
well
plate
seed
uninfect
cellsml
control
egfp
signal
well
record
day
post
plate
describ
screen
assay
experi
repeat
three
separ
day
intraexperiment
variat
determin
calcul
mean
egfp
signal
virusinfect
control
cell
plate
within
day
interexperiment
variat
determin
calcul
mean
egfp
signal
experi
perform
three
separ
day
standard
deviat
sd
coeffici
variat
cv
signal
ratio
control
versu
virusinfect
cell
calcul
intraand
interreproduc
experi
demonstr
specif
assay
defin
abil
detect
select
sarscov
inhibitor
serial
dilut
antibodi
prepar
phosphat
buffer
salin
pb
sigma
st
loui
mo
analyz
parallel
sarscov
tgev
cytotox
screen
assay
describ
identifi
potenti
class
pharmacolog
agent
activ
sarscov
rang
previous
describ
antivir
compound
test
tabl
antivir
agent
includ
compound
target
viral
cellular
factor
ribavirin
et
al
azt
furman
et
al
zhang
et
al
includ
repres
wide
use
class
nucleosid
analog
inhibit
viral
polymeras
select
antivir
proteas
inhibitor
implic
activ
sarscov
yamamoto
et
al
wu
et
al
chu
et
al
merit
inclus
lopinavirritonavir
rang
nonspecif
antivir
reagent
includ
aurintricarboxyl
acid
ata
dextran
sulfat
novaron
glycirrhizin
snitrosonacetylpenicillamin
includ
due
previous
report
activ
sarscov
unclear
mechan
action
cinatl
et
al
keyaert
et
al
addit
varieti
antivir
compound
act
cellular
target
includ
map
kinas
inhibitor
inhibitor
ace
inhibitor
tabl
separ
randomli
chosen
compound
proprietari
chemic
librari
test
compound
dissolv
mm
dimethylsulphoxid
dmso
sigma
dilut
cell
cultur
medium
final
dmso
concentr
provid
conveni
indic
cell
highthroughput
screen
assay
stabl
cell
line
constitut
express
egfp
gener
cell
line
transduc
packag
retroviru
carri
egfp
gene
clone
isol
cell
line
subsequ
character
studi
cell
subject
fac
analysi
egfp
express
select
clone
exhibit
profil
high
mean
fluoresc
intens
homogen
signal
fig
egfp
express
clone
evalu
suscept
viru
infect
show
clone
suscept
either
sarscov
tgev
measur
cpe
induct
viru
challeng
data
shown
growth
characterist
clone
similar
parent
cell
line
data
shown
indic
egfp
express
affect
cell
prolifer
expect
transduc
cell
show
exponenti
growth
depend
initi
cell
densiti
repres
exampl
shown
fig
moreov
growth
experi
show
final
seed
densiti
cellsml
suitabl
keep
cell
exponenti
growth
phase
throughout
assay
period
take
select
criteria
account
clone
clone
data
shown
select
indic
cell
seed
densiti
cellsml
screen
assay
ensur
reliabl
screen
platform
reduc
egfp
express
valid
marker
virusinduc
cytopath
activ
robust
specif
assay
determin
valid
use
quantif
report
gene
egfp
measur
viral
activ
determin
viru
titrat
experi
calcul
titer
base
cpe
egfp
measur
titrat
experi
show
virusconcentr
depend
loss
egfp
express
viru
titer
score
method
good
agreement
tabl
confirm
egfp
express
serv
marker
activ
two
virus
assay
sensit
determin
lowest
viru
titer
result
least
twofold
decreas
egfp
signal
indic
cell
show
signific
reduct
egfp
signal
viru
titer
low
ccid
sarscov
ccid
tgev
fig
confirm
measur
egfp
express
cell
allow
sensit
detect
low
level
viru
assay
robust
intraand
interassay
variat
assess
multipl
egfp
measur
day
sever
day
signal
ratio
uninfect
control
cell
virusinfect
cell
vari
suggest
suffici
dynam
rang
measur
antivir
activ
test
compound
tabl
specif
assay
defin
abil
detect
select
sarscov
inhibitor
determin
test
antibodi
specif
sarscov
receptor
screen
assay
antibodi
show
select
potent
inhibit
sarscov
noncytotox
concentr
fig
tabl
antivir
ec
valu
measur
viru
inhibit
base
egfp
signal
tabl
use
cpe
readout
data
shown
show
close
correl
egfp
express
viral
cytopath
activ
togeth
valid
experi
show
screen
system
reproduc
specif
detect
agent
activ
sarscov
sarscov
screen
system
initi
use
test
select
pharmacolog
agent
compound
includ
agent
target
differ
viral
factor
well
inhibitor
cellular
kinas
ace
tabl
one
ace
inhibitor
tabl
show
select
antivir
activ
sarscov
use
cytotoxicityantivir
activ
si
criterion
howev
cell
line
appear
sensit
cytotox
effect
compound
cell
line
indic
ace
inhibitor
may
exhibit
cellular
effect
observ
assay
system
test
agent
show
antivir
activ
cytotox
concentr
tabl
data
shown
test
possibl
use
assay
system
highthroughput
set
total
small
molecul
compound
test
select
antivir
activ
sarscov
sixtyfour
compound
activ
sarscov
assay
compound
exhibit
cytotoxicityantivir
activ
si
least
list
compound
ar
tabl
ec
valu
rang
antisarscov
activ
noncytotox
compound
show
tgevsarscov
si
least
absenc
cytotox
effect
two
indic
cell
line
compound
n
p
tabl
togeth
result
show
combin
assay
use
screen
system
potenti
provid
effici
basi
drug
discoveri
import
aspect
drug
screen
new
viral
diseas
choic
assay
system
drug
candid
fulfil
number
requir
regard
potenc
target
specif
cytotox
thu
screen
system
design
three
parallel
type
assay
similar
setup
readout
evalu
paramet
concurr
initi
screen
phase
suscept
cell
line
equip
egfp
report
gene
use
quantif
cytotox
sarscov
tgev
activ
assay
system
readili
appli
highthroughput
screen
mani
advantag
assay
base
labori
subject
score
cpe
plaqu
format
assay
system
describ
studi
requir
minim
manipul
assay
setup
stain
wash
fixat
manual
inspect
tissu
cultur
plate
especi
advantag
work
hazard
virus
sarscov
strategi
use
parallel
counterscreen
chemic
compound
porcinespecif
member
coronaviru
famili
employ
select
drug
candid
high
specif
human
sarscov
highli
virusspecif
compound
like
exhibit
welldefin
singl
viral
target
bind
site
greatli
facilit
structureact
analysi
optim
activ
compound
identifi
initi
screen
thu
platform
three
parallel
screen
assay
describ
obtain
data
potenti
use
compound
initi
screen
step
simpl
infect
assay
therefor
speed
downstream
drug
develop
cours
conceiv
potent
antivir
drug
candid
develop
compound
target
multipl
coronavirus
compound
activ
coronavirus
may
select
data
obtain
screen
system
analyz
separ
analyz
panel
report
antivir
compound
differ
mechan
activ
test
screen
system
find
ace
inhibitor
show
select
activ
sarscov
line
report
usag
receptor
viru
li
et
al
ribavarin
although
activ
wide
rang
virus
use
sar
therapi
et
al
shown
studi
inact
sarscov
vitro
noncytotox
concentr
line
previou
report
tan
et
al
cinatl
et
al
wu
et
al
yi
et
al
variat
result
obtain
studi
novaron
glycirrihizin
snitrosonacetylpenicillamin
compar
previous
publish
result
may
due
assay
condit
includ
viru
strain
multipl
infect
detect
method
compound
concentr
handl
cinatl
et
al
keyaert
et
al
notabl
independ
group
also
observ
lack
antisarscov
activ
glycyrrhizin
hertzig
et
al
yi
et
al
tabl
screen
activ
valid
gener
antiviraland
chemic
librari
compound
assay
system
also
evalu
set
chemic
librari
screen
compound
select
activ
sarscov
noncytotox
compound
concentr
identifi
librari
screen
compound
show
potenti
optim
potent
inhibitor
sarscov
merit
detail
character
regard
mechan
action
conclus
report
describ
robust
screen
system
identif
drug
candid
select
activ
sarscov
screen
system
meet
requir
success
highthroughput
assay
minim
manipul
assay
setup
low
sampl
volum
autom
detect
endpoint
furthermor
system
offer
consider
benefit
first
round
screen
regard
fig
titrat
antibodi
cell
antibodi
show
concentrationdepend
protect
egfp
signal
sarscov
challeng
quadrupl
well
infect
treat
cell
shown
number
indic
test
antibodi
concentr
gml
vc
viru
control
cc
cell
control
mc
medium
control
ing
select
specif
toxic
compound
result
improv
data
set
initi
screen
comparison
exist
assay
base
simpler
observ
plaqu
format
analysi
cpe
system
eas
handl
good
level
contain
well
suit
drug
discoveri
sarscov
applic
emerg
highrisk
pathogen
virus
